ArticlePlant biotechnology journal2025
PME10 Is a Pectin Methylesterase Driving PME Activity and Immunity Against Botrytis cinerea in Grapevine (Vitis vinifera L.).
Article in Plant biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Integrated Transcriptomic, Enzymatic, and Immunolocalization Analysis Reveals Pectin Remodeling-Mediated Defense AgainstCurrent issues in molecular biology · 2026Article
- Pectin under stress: Pectin methylesterases at the core of cell wall remodeling, integrity sensing, and signaling in plants.Plant communications · 2026Review
- Advances in the functional research of pectin methylesterases in Arabidopsis thaliana.BMC plant biology · 2026Review
- From Waste to Defense: Agro-Industrial Byproducts as Sources of Biopesticides and Bioelicitors for Crop Protection.Journal of agricultural and food chemistry · 2026Review
- Biorefining of Anaerobic Digestates for the Recovery of Biostimulants and Bioelicitors for Immune Priming and Plant Protection.Environmental science & technology · 2025Article
- Transient Overexpression ofPlants (Basel, Switzerland) · 2025Article
- Identification and genome insights intoFrontiers in plant science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Botrytis cinerea (Bc) is a major pathogen of cultivated grapevine (Vitis vinifera L.), with cell wall (CW) remodelling playing a critical role in fungal colonisation. CW-modifying enzymes, particularly pectin methylesterases (PMEs), produced by both host and pathogen, influence CW integrity and the outcome of infection. To explore the role of CW composition and remodelling in grapevine's response to Bc, we inoculated three genotypes with varying susceptibility at full flowering. Biochemical analysis of flowers and ripe berry skins revealed that the tolerant genotype exhibited significantly higher PME activity postinfection compared with the susceptible ones. Unbiased transcriptome analysis of infected flower tissues showed a more intense transcriptional response in the susceptible genotype, suggesting an ultimately ineffective attempt to restrict fungus spread. Expression profiling of 62 PME genes in this data set and public Bc-infected berry transcriptomes identified PME10 as the most strongly induced gene upon infection. PME10 knockout mutants displayed reduced PME activity and heightened susceptibility, while overexpression lines showed enhanced PME activity and reduced disease symptoms. Gene co-expression network analysis highlighted WRKY03, a defence-related transcription factor, as a putative regulator of PME10. DAP-seq, DAP-qPCR and dual luciferase assays confirmed direct binding and activation of the PME10 promoter by WRKY03. Altogether, this study demonstrates that PME10 is a functional PME contributing to grapevine immunity against B. cinerea, establishing it as a key component of the grapevine defence machinery against fungal pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.